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TO THE EDITORLeft Atrial Appendage
Occlusion Devices Versus
Pharmacological Agents
for Stroke Prevention in
Atrial Fibrillation
Testing the Noninferiority MarginsIn studying the risk of stroke in patients with atrial
ﬁbrillation, the reports by Bajaj et al. (1) and Ruff et al.
(2) represent the most updated analyses focused,
respectively, on left atrial appendage occlusion
devices (AODs) and pharmacological agents (i.e.,
warfarin and novel oral anticoagulants [NOACs]).
According to the endpoint of stroke or systemic
embolism, the crude event rates found in these
analyses were: warfarin 1,107 of 29,229 (3.79%) (2);
any NOAC 911 of 29,312 (3.11%) (2); and AODs 11 of
1,107 (0.99%) (1). The place in therapy of warfarin in
this disease condition is well established, and the
pros and cons of this drug are well known. On the
other hand, the therapeutic placement of NOACs
and, especially, AODs is still a matter of debate
(2–4). Although no randomized trial has compared
NOACs with AODs, the indirect comparison suggests
no proof of difference (3), which is, however, an
inconclusive result.
Despite the indirect nature of the comparison be-
tween AODs and NOACs, and the inherent limitations,
maximizing the evidence currently available can be
worthwhile, and in this framework, studying the
noninferiority of AODs versus NOACs can be of
interest.
Testing noninferiority is particularly straightfor-
ward when the information on margins is combined
with standard Forest plots. Margins represent a
threshold between clinically relevant incremental
beneﬁts and irrelevant ones, and can be retrieved
from statistical power information of original trials.
We have applied this approach to evaluate the
noninferiority of AODs versus NOACs in atrial ﬁbril-
lation (endpoint: stroke or systemic embolism).
The clinical material was the same as previouslyreported (1,2), the only difference being that the re-
sults were re-expressed as risk difference (RD)
instead of relative risk. To evaluate this indirect
comparison, we simply analyzed the crude event
rates, and we then estimated the RD, along with its
95% conﬁdence interval (CI), according to standard
statistics (5). The noninferiority margin was set at the
same value (RD ¼ 2.5%) adopted in pivotal trials
comparing NOACs versus warfarin (6). Hence, the
Forest plot of our analysis contained a single dataset
(i.e., the RD for the indirect comparison of AODs vs.
NOACs) and the noninferiority interval for this
parameter. This interval ranged from N to þ2.5%,
whereas failure in demonstrating noninferiority
corresponded to RD values exceeding þ2.5%.
Our analysis determined a RD of 2.1% (95%
CI: 2.7% to 1.5%) in favor of AODs in comparison
with NOACs. The noninferiority criterion was largely
satisﬁed because the 95% CI of RD remained entirely
below the noninferiority margin at RD ¼ þ2.5%). In
addition, these results also supported the conclusion
that AODs are signiﬁcantly superior to NOACs
because the upper limit of the 95% CI did not reach
the identity line (at RD ¼ 0).
Of course, the safety of these interventions (1,2)
is another important factor to appropriately deﬁne
their therapeutic role. It should also be stressed that
our statistical analysis was a very simpliﬁed one,
since we directly relied on crude rates. Despite these
limitations, a favorable therapeutic proﬁle of AODs
clearly emerges from the present analysis. Needless to
say, randomized studies comparing AODs with NOACs
are urgently required to shed light on this topic.*Andrea Messori, PharmD
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Testing the Noninferiority MarginsWe thank Messori et al. for their interest in our recent
systematic review of outcomes after implantation of
percutaneous left atrial appendage (LAA) occlusion
devices (1). The authors have used a novel statistical
analysis to raise the possibility that LAA occlusion
devices might be superior to newer oral anti-
coagulants (NOACs) in preventing stroke or systemic
embolism. This is potentially a thought-provoking
observation in favor of the efﬁcacy of the
percutaneous closure of the LAA.
The pivotal noninferiority randomized, controlled
trials like RE-LY (Randomized Evaluation of Long-
Term Anticoagulant Therapy), ARISTOTLE (Apixaban
for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation), and ROCKET-AF (Rivar-
oxaban Once Daily Oral Direct Factor Xa Inhibitor
Compared with Vitamin K Antagonism for Preventionof Stroke and Embolism Trial in Atrial Fibrillation)
have tested whether individual NOACs were non-
inferior to warfarin in preventing stroke or systemic
embolism (2–4). The noninferiority margin in these
trials was derived from an earlier meta-analysis of
outcomes after administration of warfarin compared
with placebo (5). The noninferiority margin was set at
half the 95% conﬁdence interval of the estimated
effect of warfarin compared with placebo. Messori
et al. have used this methodology in a unique
quantitative-analytic framework to calculate the
difference in outcomes between LAA occlusion
devices and NOACs.
Although the superiority of LAA occlusion devices
over NOACs is a possibility, the analysis described
by Messori et al. is also somewhat provocative. We
agree that this is a very interesting hypothesis and
therefore would need to be veriﬁed in head-to-head
randomized, controlled trials before widespread
acceptability in clinical practice.Akhil Parashar, MD
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